Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma

Over 8 years, dabrafenib and trametinib showed improved survival vs placebo in stage III melanoma, but overall and melanoma-specific benefits were not statistically significant.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.